Donate to Illuminate Contact TSF
Facebook Logo Twitter Logo Youtube Logo Instagram Logo LinkedIn Logo TikTok Logo Blue Sky Logo
Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

Journal: Journal of Neurological Sciences; March 1, 2024

Author(s): Negar Molazadeh, Philippe A. Bilodeau, Rebecca Salky, Gauruv Bose, Itay Lotan, Gabriela Romanow, Monique R. Anderson, Marcelo Matiello, Tanuja Chitnis, Michael Levy

What predicts a relapsing disease course after the first demyelination event in MOGAD patients?

MOGAD may manifest as a one-time occurrence of demyelination (monophasic) or as multiple episodes (relapsing) over time. This study followed 124 MOGAD patients (77 female) for a median duration of 4.8 years to determine what factors could predict whether patients would have relapses based on the first occurrence. During the follow-up time, 50 of the patients (40.3%) remained monophasic and 74 (59.7%) developed a relapsing course. The average time between the first episode and the second episode was 3 months. Relapsing disease was less likely if maintenance therapy with intravenous immunoglobulin, rituximab, and mycophenolate mofetil was initiated after the first attack. If the first attack itself involved multiple demyelination events, a relapsing course was more likely.

Free Access: Patient access via email

read the abstract

Industry Partners

Community Partners

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.